Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers (Basel). 2021;13:4287. doi:10.3390/cancers13174287.

Union for International Cancer Control Globocan. GLOBOCAN 2020: new global cancer Data. UICC; 2020.

International Agency for Research on Cancer World Health Organization. Global Cancer Observatory. Indonesia. Lyon, France: International Agency for Research on Cancer; 2020.

Badan Penelitian dan Pengembangan Kesehatan -. Laporan Provinsi DI Yogyakarta Riskesdas 2018. [Report of the Special Region of Yogyakarta Basic Health Research 2018.] Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan; 2019. Indonesian.

Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 2021;22:1139-50. doi: 10.1016/S1470-2045(21)00288-6.

Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res 2020;10:1045-67.

Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67:93-9. doi: 10.3322/caac. 21388.

Li MH, Hou CL, Wang C, Sun AJ. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women. Pathol Res Pract 2016;212:252-7. doi: 10.1016/j.prp.2015.11.019.

Sutthipongsupa T, Wongchansom K, Wuttipanich P, Charoenpitakchai M. A comparison study of molecular classification of primary invasive breast carcinoma and corresponding metastatic carcinoma in axillary lymph nodes by immunohistochemistry. Asian Arch Pathol 2020;2:20-32.

McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22:276-82.

Ieni A, Barresi V, Caltabiano R, et al. Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. Onco Targets Ther 2014;7:1267-72. doi: 10.2147/OTT.S65294.

Cai M, Li M, Lv H, et al. HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases. BMC Cancer 2023;23:656. doi: 10.1186/s12885-023-11134-4.

Almstedt K, Krauthauser L, Kappenberg F, et al. Discordance of HER2-Low between primary tumors and matched distant metastases in breast cancer. Cancers (Basel) 2023;15:1413. doi: 10.3390/cancers15051413.

Valent A, Penault-Llorca F, Cayre A, Kroemer G. Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. Cancer Genet 2013;206:37-41. doi: 10.1016/ j.cancergen.2012.12.001.

Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 2020;54:34-44. doi: 10.4132/jptm. 2019.11.03.

Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. J Nucl Med 2016;57:1523-8. doi: 10.2967/jnumed.115.172031.

Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Emerging targeted therapies for HER2-positive breast cancer. Cancers (Basel) 2023;15:1987. doi:10.3390/cancers15071987.

Widiana IK, Irawan H. Clinical and subtypes of breast cancer in Indonesia. Asian Pac J Cancer Care 2020;5:281-5. doi: 10.31557/apjcc.2020.5.4. 281-285.

Mogica JP, Tang H, Liang Y, et al. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: a single institution experience and review of the literature. Breast 2023;72:103586. doi: 10.1016/ j.breast.2023.103586.

Canadian Cancer Society. Targeted therapy drugs for HER2-positive breast cancer. Toronto, Canada: Canadian Cancer Society;2025.

Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 2023;22:101. doi: 10.1038/s41573-022-00579-0.

Peralta-Castillo G, Maffuz-Aziz A, Sierra-Murguía M, Rodriguez-Cuevas S. Neutrophil-lymphocyte index as prognostic factor for overall survival and disease-free survival in breast cancer patients. Revista de Senología y Patología Mamaria J Senol Breast Dis 2020;33:137-44. doi: 10.1016/j.senol.2020.06.004.